The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 10, 2018

Filed:

Aug. 26, 2016
Applicant:

Merrimack Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Jason Baum, Needham, MA (US);

Bryan Johnson, Natick, MA (US);

Alexey Alexandrovich Lugovskoy, Woburn, MA (US);

Lihui Xu, Chestnut Hill, MA (US);

Neeraj Kohli, Brighton, MA (US);

Jonathan Basil Fitzgerald, Arlington, MA (US);

Sharlene Adams, Waltham, MA (US);

Assignee:

Merrimack Pharmaceuticals, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); C07K 16/32 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); C07K 16/2869 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.


Find Patent Forward Citations

Loading…